<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02821910</url>
  </required_header>
  <id_info>
    <org_study_id>1361.1</org_study_id>
    <secondary_id>2015-005082-23</secondary_id>
    <nct_id>NCT02821910</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets</brief_title>
  <official_title>Relative Bioavailability of Two FDC Tablet Strengths of Empagliflozin/Linagliptin/Metformin Extended Release Compared to the Free Combination of Empagliflozin, Linagliptin and Metformin Extended Release Following Oral Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed
      fixed dose combinations (FDC) tablets containing empagliflozin, linagliptin &amp; metformin
      extended release (XR) and the single tablets of empagliflozin, linagliptin and metformin XR
      administered simultaneously.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz)</measure>
    <time_frame>up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of empagliflozin in plasma (Cmax)</measure>
    <time_frame>up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours (AUC0-72)</measure>
    <time_frame>up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of linagliptin in plasma (Cmax)</measure>
    <time_frame>up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz)</measure>
    <time_frame>up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of metformin in plasma (Cmax)</measure>
    <time_frame>up to 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity)</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity)</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity)</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>High dose, fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose, fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 fixed dose combination (FDC) tablet vs. 4 single tablets under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose, fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed</intervention_name>
    <description>High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet</description>
    <arm_group_label>High dose, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR</intervention_name>
    <description>1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets</description>
    <arm_group_label>High dose, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted</intervention_name>
    <description>High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet</description>
    <arm_group_label>High dose, fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR</intervention_name>
    <description>1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets</description>
    <arm_group_label>High dose, fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed</intervention_name>
    <description>Low dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet</description>
    <arm_group_label>Low dose, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR</intervention_name>
    <description>1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets</description>
    <arm_group_label>Low dose, fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy male or female subjects according to the investigator's assessment, based on a
             complete medical history including a physical examination, vital signs (blood
             pressure, pulse rate), 12-lead electrocardiogram, and clinical laboratory tests

          -  Age of 18 to 55 years (incl.)

          -  BMI of 18.5 to 29.9 kg/m2 (incl.)

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and local legislation

          -  Male subjects, or female subjects who meet any of the following criteria starting from
             at least 30 days before the first administration of trial medication and until 30 days
             after trial completion:

        Use of adequate contraception, e.g. any of the following methods plus condom: implants,
        injectables, combined oral or vaginal contraceptives, intrauterine device Sexually
        abstinent A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)
        Surgically sterilised (including hysterectomy) Postmenopausal, defined as at least 1 year
        of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous levels of
        follicle-stimulating hormone above 40 U/L and estradiol below 30 ng/L is confirmatory)

        Exclusion criteria:

          -  Any finding in the medical examination (including blood pressure, pulse rate or
             electrocardiogram) is deviating from normal and judged as clinically relevant by the
             investigator

          -  Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg,
             diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the
             range of 45 to 90 bpm

          -  Any laboratory value outside the reference range that the investigator considers to be
             of clinical relevance

          -  Any evidence of a concomitant disease judged as clinically relevant by the
             investigator

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with
             the pharmacokinetics of the trial medication (except appendectomy and simple hernia
             repair)

          -  Diseases of the central nervous system (including but not limited to any kind of
             seizures or stroke), and other relevant neurological or psychiatric disorders

          -  Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>June 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2016</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

